Charles River Labs Announces Retirement of Chief Commercial Officer and Successor Appointment

Details

announced on January 9, 2024, the retirement of William D. Barbo, its Corporate Executive Vice President and Chief Commercial Officer, effective at the end of 2024. In preparation for his retirement, Barbo will continue to serve as an Executive Vice President and strategic advisor until the transition is complete. Kristen Eisenhauer has been appointed as the new Senior Vice President, Chief Commercial Officer, effective immediately. Eisenhauer brings 20 years of experience with the Company and has held various leadership roles.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.